Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Bonneau, N. Duggan, M. Hussey, L. Ciuclan, C. Tomlins, S. Roberts, L.D. Dang, R. Allen, D. Rowlands, M. Thomas (Horsham, United Kingdom). Effect of long-term imatinib treatment in a severe preclinical PAH rat model: An insight into pulmonary perfusion using a novel casting method. Eur Respir J 2012; 40: Suppl. 56, 3168

Member's Comments

No comment yet.

Related content which might interest you: Enhanced efficacy of combining imatinib with sildenafil in a rodent model of pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 SERCA2a gene therapy ameliorates pulmonary hypertension in a pig model: comparison of different delivery methods and therapeutic effect Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018 Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011 New therapeutic targets in pulmonary arterial hypertension (PAH): moving from preclinical data to phase 2 studies Source: International Congress 2018 – New trends in the management of pulmonary hypertension Year: 2018 A new method to estimate the long-term effect of immunosuppressants and vasodilator therapies on lung function outcomes in systemic sclerosis patients Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 The effect of combined therapy using rosuvastatin and dihydroarteminin in a pulmonary malaria mouse model. Source: International Congress 2018 – Role of microbial exposure and inflammation in lung injury Year: 2018 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Evaluation of novel LOXL2-selective inhibitors in models of pulmonary fibrosis Source: International Congress 2017 – Cellular signalling pathways in pulmonary fibrosis Year: 2017 Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights Source: Eur Respir J 2015; 46: 414-421 Year: 2015 A novel murine model of severe pulmonary arterial hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010 Effects of intermittent hypoxia on pulmonary haemodynamics: animal models vs studies in humans Source: Annual Congress 2003 - Sadoul Lecture symposium Year: 2003 New therapeutic approach for the treatment of monocrotaline-induced pulmonary hypertension with imatinib Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation Source: Virtual Congress 2020 – Updated assessment and treatment of pulmonary arterial hypertension Year: 2020 Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease Source: Eur Respir J 2003; 22: Suppl. 45, 474s Year: 2003 Longitudinal micro-CT-derived biomarkers: the new standard readouts for preclinical evaluation of pulmonary fibrosis and therapy Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues Year: 2019 Applying pharmacogenomics to pulmonary arterial hypertension (PAH): A target-based approach to therapy Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019 Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics Source: International Congress 2015 – New models for treating airway diseases Year: 2015